Skip to main content
Top
Gepubliceerd in:

01-10-2010

Psychometric evaluation of the functional assessment of HIV Infection (FAHI) questionnaire and its usefulness in clinical trials

Auteurs: Muriel Viala-Danten, Dominique Dubois, Hélène Gilet, Silas Martin, Katrien Peeters, David Cella

Gepubliceerd in: Quality of Life Research | Uitgave 8/2010

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Purpose

To evaluate psychometric properties of the Functional Assessment of Human Immunodeficiency Virus Infection (FAHI) questionnaire, a 47-item disease-specific instrument evaluating Health-Related Quality of Life (HRQL) in human immunodeficiency virus (HIV)-infected patients.

Methods

Treatment-experienced HIV-infected patients from two clinical programmes (N = 565; N = 1,096) completed the FAHI at Baseline and after 24 weeks of treatment. Psychometric properties of the FAHI were assessed in both trial populations, including minimal important differences (MIDs) calculations. Links between HRQL assessed by FAHI Total score, and biological endpoints were explored by regression analysis and mean score comparisons.

Results

Cronbach’s alphas ranged from 0.72 to 0.94. Most items met convergent and discriminant validity criteria. Better FAHI scores were seen for patients in earlier HIV stages. Responsiveness was demonstrated with changes in FAHI scores significantly linked to change in EQ-5D score. Depending on methods used, MIDs ranged from 3.2 to 14 for FAHI Total score. Small association was found between FAHI Total score and CD4 count and viral load (r-square < 3%). Mean changes in FAHI scores were not statistically related to viral response.

Conclusions

The FAHI demonstrated acceptable psychometric properties in two independent populations. HRQL assessment enabled detection of changes in patients’ health status not revealed by traditional efficacy endpoints.
Literatuur
1.
go back to reference Detels, R., Munoz, A., McFarlane, G., Kingsley, L. A., Margolick, J. B., Giorgi, J., et al. (1998). Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. The Journal of American Medical Association, 280(17), 1497–1503.CrossRef Detels, R., Munoz, A., McFarlane, G., Kingsley, L. A., Margolick, J. B., Giorgi, J., et al. (1998). Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. The Journal of American Medical Association, 280(17), 1497–1503.CrossRef
2.
go back to reference Palella, F. J., Jr., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., et al. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. The New England Journal of Medicine, 338(13), 853–860.CrossRefPubMed Palella, F. J., Jr., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., et al. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. The New England Journal of Medicine, 338(13), 853–860.CrossRefPubMed
3.
go back to reference Walensky, R. P., Paltiel, A. D., Losina, E., Mercincavage, L. M., Schackman, B. R., Sax, P. E., et al. (2006). The survival benefits of AIDS treatment in the United States. Journal of Infectious Diseases, 194(1), 11–19.CrossRefPubMed Walensky, R. P., Paltiel, A. D., Losina, E., Mercincavage, L. M., Schackman, B. R., Sax, P. E., et al. (2006). The survival benefits of AIDS treatment in the United States. Journal of Infectious Diseases, 194(1), 11–19.CrossRefPubMed
4.
go back to reference Mrus, J. M., Williams, P. L., Tsevat, J., Cohn, S. E., & Wu, A. W. (2005). Gender differences in health-related quality of life in patients with HIV/AIDS. Quality of Life Research, 14(2), 479–491.CrossRefPubMed Mrus, J. M., Williams, P. L., Tsevat, J., Cohn, S. E., & Wu, A. W. (2005). Gender differences in health-related quality of life in patients with HIV/AIDS. Quality of Life Research, 14(2), 479–491.CrossRefPubMed
5.
go back to reference van Sighem, A. I., van de Wiel, M. A., Ghani, A. C., Jambroes, M., Reiss, P., Gyssens, I. C., et al. (2003). Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS, 17(15), 2227–2236.CrossRefPubMed van Sighem, A. I., van de Wiel, M. A., Ghani, A. C., Jambroes, M., Reiss, P., Gyssens, I. C., et al. (2003). Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS, 17(15), 2227–2236.CrossRefPubMed
6.
go back to reference Agrawal, L., Lu, X., Jin, Q., & Alkhatib, G. (2006). Anti-HIV therapy: Current and future directions. Current Pharmaceutical Design, 12(16), 2031–2055.CrossRefPubMed Agrawal, L., Lu, X., Jin, Q., & Alkhatib, G. (2006). Anti-HIV therapy: Current and future directions. Current Pharmaceutical Design, 12(16), 2031–2055.CrossRefPubMed
7.
go back to reference Montessori, V., Press, N., Harris, M., Akagi, L., & Montaner, J. S. (2004). Adverse effects of antiretroviral therapy for HIV infection. Canadian Medical Association Journal, 170(2), 229–238.PubMed Montessori, V., Press, N., Harris, M., Akagi, L., & Montaner, J. S. (2004). Adverse effects of antiretroviral therapy for HIV infection. Canadian Medical Association Journal, 170(2), 229–238.PubMed
8.
go back to reference Carr, A., Samaras, K., Burton, S., Law, M., Freund, J., Chisholm, D. J., et al. (1998). A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS, 12(7), F51–F58.CrossRefPubMed Carr, A., Samaras, K., Burton, S., Law, M., Freund, J., Chisholm, D. J., et al. (1998). A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS, 12(7), F51–F58.CrossRefPubMed
9.
go back to reference Miller, J., Carr, A., Emery, S., Law, M., Mallal, S., Baker, D., et al. (2003). HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Medicine, 4(3), 293–301.CrossRefPubMed Miller, J., Carr, A., Emery, S., Law, M., Mallal, S., Baker, D., et al. (2003). HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Medicine, 4(3), 293–301.CrossRefPubMed
10.
go back to reference Gulick, R. M. (1997). Current antiretroviral therapy: An overview. Quality of Life Research, 6(6), 471–474.CrossRefPubMed Gulick, R. M. (1997). Current antiretroviral therapy: An overview. Quality of Life Research, 6(6), 471–474.CrossRefPubMed
11.
go back to reference Leplege, A., Rude, N., Ecosse, E., Ceinos, R., Dohin, E., & Pouchot, J. (1997). Measuring quality of life from the point of view of HIV-positive subjects: The HIV-QL31. Quality of Life Research, 6(6), 585–594.CrossRefPubMed Leplege, A., Rude, N., Ecosse, E., Ceinos, R., Dohin, E., & Pouchot, J. (1997). Measuring quality of life from the point of view of HIV-positive subjects: The HIV-QL31. Quality of Life Research, 6(6), 585–594.CrossRefPubMed
12.
go back to reference Reynolds, N. R. (2004). Adherence to antiretroviral therapies: state of the science. Current HIV Research, 2(3), 207–214.CrossRefPubMed Reynolds, N. R. (2004). Adherence to antiretroviral therapies: state of the science. Current HIV Research, 2(3), 207–214.CrossRefPubMed
13.
go back to reference Chassany, O., Sagnier, P., Marquis, P., Fullerton, S., Aaronson, N., & ERIQA Group. (2002). Patient-reported outcomes: The example of health-related quality of life—A European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process. Drug Information Journal, 36, 209–238. Chassany, O., Sagnier, P., Marquis, P., Fullerton, S., Aaronson, N., & ERIQA Group. (2002). Patient-reported outcomes: The example of health-related quality of life—A European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process. Drug Information Journal, 36, 209–238.
14.
go back to reference Lin, M. K., Wu, A. W., & Revicki, D. A. (2002). Incorporating quality of life measures in HIV clinical trials. HIC Clinical Trials, 3(3), 202–218.CrossRef Lin, M. K., Wu, A. W., & Revicki, D. A. (2002). Incorporating quality of life measures in HIV clinical trials. HIC Clinical Trials, 3(3), 202–218.CrossRef
15.
go back to reference Lohr, K. N., Aaronson, N. K., Alonso, J., Burnam, M. A., Patrick, D. L., Perrin, E. B., et al. (1996). Evaluating quality-of-life and health status instruments: Development of scientific review criteria. Clinical Therapeutics, 18(5), 979–992.CrossRefPubMed Lohr, K. N., Aaronson, N. K., Alonso, J., Burnam, M. A., Patrick, D. L., Perrin, E. B., et al. (1996). Evaluating quality-of-life and health status instruments: Development of scientific review criteria. Clinical Therapeutics, 18(5), 979–992.CrossRefPubMed
17.
go back to reference Clayson, D. J., Wild, D. J., Quarterman, P., Duprat-Lomon, I., Kubin, M., & Coons, S. J. (2006). A comparative review of health-related quality-of-life measures for use in HIV/AIDS clinical trials. PharmacoEconomics, 24(8), 751–765.CrossRefPubMed Clayson, D. J., Wild, D. J., Quarterman, P., Duprat-Lomon, I., Kubin, M., & Coons, S. J. (2006). A comparative review of health-related quality-of-life measures for use in HIV/AIDS clinical trials. PharmacoEconomics, 24(8), 751–765.CrossRefPubMed
18.
go back to reference Cella, D. F., McCain, N. L., Peterman, A. H., Mo, F., & Wolen, D. (1996). Development and validation of the functional assessment of human immunodeficiency virus infection (FAHI) quality of life instrument. Quality of Life Research, 5(4), 450–463.CrossRefPubMed Cella, D. F., McCain, N. L., Peterman, A. H., Mo, F., & Wolen, D. (1996). Development and validation of the functional assessment of human immunodeficiency virus infection (FAHI) quality of life instrument. Quality of Life Research, 5(4), 450–463.CrossRefPubMed
19.
go back to reference Cella, D. F., Tulsky, D. S., Gray, G., et al. (1993). The functional assessment of cancer therapy scale: Development and validation of the general measure. Journal of Clinical Oncology, 11(3), 570–579.PubMed Cella, D. F., Tulsky, D. S., Gray, G., et al. (1993). The functional assessment of cancer therapy scale: Development and validation of the general measure. Journal of Clinical Oncology, 11(3), 570–579.PubMed
20.
go back to reference Peterman, A. H., Cella, D., Mo, F., & McCain, N. (1997). Psychometric validation of the revised functional assessment of human immunodeficiency virus infection (FAHI) quality of life instrument. Quality of Life Research, 6, 572–584.CrossRefPubMed Peterman, A. H., Cella, D., Mo, F., & McCain, N. (1997). Psychometric validation of the revised functional assessment of human immunodeficiency virus infection (FAHI) quality of life instrument. Quality of Life Research, 6, 572–584.CrossRefPubMed
21.
go back to reference Wu, A. W., Rubin, H. R., Mathews, W. C., Ware, J. E., Jr., Brysk, L. T., Hardy, W. D., et al. (1991). A health status questionnaire using 30 items from the medical outcomes study. Preliminary validation in persons with early HIV infection. Medical Care, 29(8), 786–798.CrossRefPubMed Wu, A. W., Rubin, H. R., Mathews, W. C., Ware, J. E., Jr., Brysk, L. T., Hardy, W. D., et al. (1991). A health status questionnaire using 30 items from the medical outcomes study. Preliminary validation in persons with early HIV infection. Medical Care, 29(8), 786–798.CrossRefPubMed
22.
go back to reference Berzon, R. A., & Lenderking, W. R. (1998). Evaluating the outcomes of HIV disease: Focus on health status measurement. A publication for members of medical outcomes trust, 3(4). Berzon, R. A., & Lenderking, W. R. (1998). Evaluating the outcomes of HIV disease: Focus on health status measurement. A publication for members of medical outcomes trust, 3(4).
23.
go back to reference Davis, E. A., & Pathak, D. S. (2001). Psychometric evaluation of four HIV disease-specific quality-of-life instruments. Annals of Pharmacotherapy, 35(5), 546–552.CrossRefPubMed Davis, E. A., & Pathak, D. S. (2001). Psychometric evaluation of four HIV disease-specific quality-of-life instruments. Annals of Pharmacotherapy, 35(5), 546–552.CrossRefPubMed
24.
go back to reference Grossman, H. A., Sullivan, P. S., & Wu, A. W. (2003). Quality of life and HIV: Current assessment tools and future directions for clinical practice. AIDS Read, 13(12), 583–587.PubMed Grossman, H. A., Sullivan, P. S., & Wu, A. W. (2003). Quality of life and HIV: Current assessment tools and future directions for clinical practice. AIDS Read, 13(12), 583–587.PubMed
25.
go back to reference Haubrich, R., Berger, D., Chiliade, P., Colson, A., Conant, M., Gallant, J., et al. (2007). Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS, 21(6), F11–F18.CrossRefPubMed Haubrich, R., Berger, D., Chiliade, P., Colson, A., Conant, M., Gallant, J., et al. (2007). Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS, 21(6), F11–F18.CrossRefPubMed
26.
go back to reference Katlama, C., Esposito, R., Gatell, J. M., Goffard, J. C., Grinsztejn, B., Pozniak, A., et al. (2007). Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS, 21(4), 395–402.CrossRefPubMed Katlama, C., Esposito, R., Gatell, J. M., Goffard, J. C., Grinsztejn, B., Pozniak, A., et al. (2007). Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS, 21(4), 395–402.CrossRefPubMed
27.
go back to reference Lazzarin, A., Campbell, T., Clotet, B., Johnson, M., Katlama, C., Moll, A., et al. (2007). Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet, 370(9581), 39–48.CrossRefPubMed Lazzarin, A., Campbell, T., Clotet, B., Johnson, M., Katlama, C., Moll, A., et al. (2007). Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet, 370(9581), 39–48.CrossRefPubMed
28.
go back to reference Madruga, J. V., Cahn, P., Grinsztejn, B., Haubrich, R., Lalezari, J., Mills, A., et al. (2007). Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet, 370(9581), 29–38.CrossRefPubMed Madruga, J. V., Cahn, P., Grinsztejn, B., Haubrich, R., Lalezari, J., Mills, A., et al. (2007). Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet, 370(9581), 29–38.CrossRefPubMed
29.
go back to reference Bonomi, A. E., Cella, D. F., Hahn, E. A., Bjordal, K., Sperner-Unterweger, B., Gangeri, L., et al. (1996). Multilingual translation of the functional assessment of cancer therapy (FACT) quality of life measurement system. Quality of Life Research, 5(3), 309–320.CrossRefPubMed Bonomi, A. E., Cella, D. F., Hahn, E. A., Bjordal, K., Sperner-Unterweger, B., Gangeri, L., et al. (1996). Multilingual translation of the functional assessment of cancer therapy (FACT) quality of life measurement system. Quality of Life Research, 5(3), 309–320.CrossRefPubMed
30.
go back to reference Eremenco, S. L., Cella, D., & Arnold, B. J. (2005). A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & The Health Professions, 28(2), 212–232.CrossRef Eremenco, S. L., Cella, D., & Arnold, B. J. (2005). A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & The Health Professions, 28(2), 212–232.CrossRef
31.
go back to reference Cronbach, L. J. (1951). Coefficient alpha and the internal structure of tests. Psychometrika, 16(3), 297–334.CrossRef Cronbach, L. J. (1951). Coefficient alpha and the internal structure of tests. Psychometrika, 16(3), 297–334.CrossRef
32.
go back to reference Nunnally, J. C., & Bernstein, I. H. (1994). Psychometric theory. New York: McGraw-Hill Inc. Nunnally, J. C., & Bernstein, I. H. (1994). Psychometric theory. New York: McGraw-Hill Inc.
33.
go back to reference Hays, R. D., Anderson, R. T., & Revicki, D. A. (1998). Assessing reliability and validity of measurement in clinical trials. In M. J. Staquet, R. D. Hays, & P. M. Fayers (Eds.), Quality of life assessment in clinical trials: methods and practice (pp. 169–182). New-York, Tokyo: Oxford. Hays, R. D., Anderson, R. T., & Revicki, D. A. (1998). Assessing reliability and validity of measurement in clinical trials. In M. J. Staquet, R. D. Hays, & P. M. Fayers (Eds.), Quality of life assessment in clinical trials: methods and practice (pp. 169–182). New-York, Tokyo: Oxford.
34.
go back to reference Hays, R. D., & Hayashi, T. (1990). Beyond internal consistency reliability: rationale and user’s guide for Multitrait analysis program on the microcomputer. Behavior Research, Methods, Instruments and Computers, 22, 167–175. Hays, R. D., & Hayashi, T. (1990). Beyond internal consistency reliability: rationale and user’s guide for Multitrait analysis program on the microcomputer. Behavior Research, Methods, Instruments and Computers, 22, 167–175.
35.
go back to reference Rabin, R., & de Charro, F. (2001). EQ-5D: A measure of health status from the EuroQol group. Annals of Medicine, 33(5), 337–343.CrossRefPubMed Rabin, R., & de Charro, F. (2001). EQ-5D: A measure of health status from the EuroQol group. Annals of Medicine, 33(5), 337–343.CrossRefPubMed
36.
go back to reference Dolan, P. (1997). Modeling valuations for EuroQol health states. Medical Care, 35(11), 1095–1108.CrossRefPubMed Dolan, P. (1997). Modeling valuations for EuroQol health states. Medical Care, 35(11), 1095–1108.CrossRefPubMed
37.
go back to reference Cohen, J. (1977). Statistical power analysis for the behavioral sciences. New York: Academic Press. Cohen, J. (1977). Statistical power analysis for the behavioral sciences. New York: Academic Press.
38.
go back to reference Jaeschke, R., Singer, J., & Guyatt, G. H. (1989). Measurement of health status. Ascertaining the minimal clinically important difference. Controlled Clinical Trials, 10(4), 407–415.CrossRefPubMed Jaeschke, R., Singer, J., & Guyatt, G. H. (1989). Measurement of health status. Ascertaining the minimal clinically important difference. Controlled Clinical Trials, 10(4), 407–415.CrossRefPubMed
39.
go back to reference Guyatt, G. H., Osoba, D., Wu, A. W., Wyrwich, K. W., Norman, G. R., & Clinical Significance Consensus Meeting Group. (2002). Methods to explain the clinical significance of health status measures. Mayo Clinic Proceedings, 77, 371–383.CrossRefPubMed Guyatt, G. H., Osoba, D., Wu, A. W., Wyrwich, K. W., Norman, G. R., & Clinical Significance Consensus Meeting Group. (2002). Methods to explain the clinical significance of health status measures. Mayo Clinic Proceedings, 77, 371–383.CrossRefPubMed
40.
go back to reference Sloan, J. A., Symonds, T., Vargas-Chanes, D., & Fridley, B. (2003). Practical guidelines for assessing the clinical significance of health related quality of life changes within clinical trials. Drug Information Journal, 37, 23–31. Sloan, J. A., Symonds, T., Vargas-Chanes, D., & Fridley, B. (2003). Practical guidelines for assessing the clinical significance of health related quality of life changes within clinical trials. Drug Information Journal, 37, 23–31.
41.
go back to reference Wyrwich, K. W., Nienaber, N. A., Tierney, W. M., & Wolinsky, F. D. (1999). Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Medical Care, 37(5), 469–478.CrossRefPubMed Wyrwich, K. W., Nienaber, N. A., Tierney, W. M., & Wolinsky, F. D. (1999). Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Medical Care, 37(5), 469–478.CrossRefPubMed
42.
go back to reference Walters, S. J., & Brazier, J. E. (2005). Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Quality of Life Research, 14(6), 1523–1532.CrossRefPubMed Walters, S. J., & Brazier, J. E. (2005). Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Quality of Life Research, 14(6), 1523–1532.CrossRefPubMed
43.
go back to reference Shikiar, R., Willian, M. K., Okun, M. M., Thompson, C. S., & Revicki, D. A. (2006). The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health and quality of life outcomes, 4, 71.CrossRefPubMed Shikiar, R., Willian, M. K., Okun, M. M., Thompson, C. S., & Revicki, D. A. (2006). The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health and quality of life outcomes, 4, 71.CrossRefPubMed
44.
go back to reference Yost, K. J., Sorensen, M. V., Hahn, E. A., Glendenning, G. A., Gnanasakthy, A., & Cella, D. (2005). Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the functional assessment of cancer therapy-biologic response modifiers (FACT-BRM) instrument. Value in Health, 8(2), 117–127.CrossRefPubMed Yost, K. J., Sorensen, M. V., Hahn, E. A., Glendenning, G. A., Gnanasakthy, A., & Cella, D. (2005). Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the functional assessment of cancer therapy-biologic response modifiers (FACT-BRM) instrument. Value in Health, 8(2), 117–127.CrossRefPubMed
46.
go back to reference Rao, D., Hahn, E. A., Cella, D., & Hernandez, L. (2007). The health related quality of life outcomes of English and Spanish speaking persons living with HIV/AIDS from the continental United States and Puerto Rico. AIDS Patient Care STDS, 21(5), 339–346.CrossRefPubMed Rao, D., Hahn, E. A., Cella, D., & Hernandez, L. (2007). The health related quality of life outcomes of English and Spanish speaking persons living with HIV/AIDS from the continental United States and Puerto Rico. AIDS Patient Care STDS, 21(5), 339–346.CrossRefPubMed
47.
go back to reference Revicki, D. A., Wu, A. W., & Murray, M. I. (1995). Change in clinical status, health status, and health utility outcomes in HIV-infected patients. Medical Care, 33(4 Suppl), AS173–AS182.PubMed Revicki, D. A., Wu, A. W., & Murray, M. I. (1995). Change in clinical status, health status, and health utility outcomes in HIV-infected patients. Medical Care, 33(4 Suppl), AS173–AS182.PubMed
48.
go back to reference Schag, C. A., Ganz, P. A., Kahn, B., & Petersen, L. (1992). Assessing the needs and quality of life of patients with HIV infection: Development of the HIV overview of problems-evaluation system (HOPES). Quality of Life Research, 1(6), 397–413.CrossRefPubMed Schag, C. A., Ganz, P. A., Kahn, B., & Petersen, L. (1992). Assessing the needs and quality of life of patients with HIV infection: Development of the HIV overview of problems-evaluation system (HOPES). Quality of Life Research, 1(6), 397–413.CrossRefPubMed
49.
go back to reference Call, S. A., Klapow, J. C., Stewart, K. E., Westfall, A. O., Mallinger, A. P., DeMasi, R. A., et al. (2000). Health-related quality of life and virologic outcomes in an HIV clinic. Quality of Life Research, 9(9), 977–985.CrossRefPubMed Call, S. A., Klapow, J. C., Stewart, K. E., Westfall, A. O., Mallinger, A. P., DeMasi, R. A., et al. (2000). Health-related quality of life and virologic outcomes in an HIV clinic. Quality of Life Research, 9(9), 977–985.CrossRefPubMed
50.
go back to reference Murri, R., Fantoni, M., Del Borgo, C., Visona, R., Barracco, A., Zambelli, A., et al. (2003). Determinants of health-related quality of life in HIV-infected patients. AIDS Care, 15(4), 581–590.CrossRefPubMed Murri, R., Fantoni, M., Del Borgo, C., Visona, R., Barracco, A., Zambelli, A., et al. (2003). Determinants of health-related quality of life in HIV-infected patients. AIDS Care, 15(4), 581–590.CrossRefPubMed
51.
go back to reference Weinfurt, K. P., Willke, R. J., Glick, H. A., Freimuth, W. W., & Schulman, K. A. (2000). Relationship between CD4 count, viral burden, and quality of life over time in HIV-1-infected patients. Medical Care, 38(4), 404–410.CrossRefPubMed Weinfurt, K. P., Willke, R. J., Glick, H. A., Freimuth, W. W., & Schulman, K. A. (2000). Relationship between CD4 count, viral burden, and quality of life over time in HIV-1-infected patients. Medical Care, 38(4), 404–410.CrossRefPubMed
52.
go back to reference Vidrine, D. J., Amick, B. C., I. I. I., Gritz, E. R., & Arduino, R. C. (2005). Assessing a conceptual framework of health-related quality of life in a HIV/AIDS population. Quality of Life Research, 14(4), 923–933.CrossRefPubMed Vidrine, D. J., Amick, B. C., I. I. I., Gritz, E. R., & Arduino, R. C. (2005). Assessing a conceptual framework of health-related quality of life in a HIV/AIDS population. Quality of Life Research, 14(4), 923–933.CrossRefPubMed
Metagegevens
Titel
Psychometric evaluation of the functional assessment of HIV Infection (FAHI) questionnaire and its usefulness in clinical trials
Auteurs
Muriel Viala-Danten
Dominique Dubois
Hélène Gilet
Silas Martin
Katrien Peeters
David Cella
Publicatiedatum
01-10-2010
Uitgeverij
Springer Netherlands
Gepubliceerd in
Quality of Life Research / Uitgave 8/2010
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-010-9674-9